Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13270195 | 0.77 | HSD17B10 (0.50) | HSD17B10ALDH1A1SMN1; SMN2GLA | |
| SCHEMBL13452492 | 0.68 | GAA (0.49) | HSD17B10ALDH1A1HTTMAPK1SMN1; SMN2 | |
| SCHEMBL13452349 | 0.66 | ALOX15 (0.47) | HSD17B10ALDH1A1HTTMAPK1SMN1; SMN2 | |
| SCHEMBL9174370 | 0.66 | GAA (0.58) | HSD17B10ALDH1A1HTTCYP1A2MAPK1 | |
| SCHEMBL5499056 | 0.66 | GAA (0.58) | HSD17B10ALDH1A1HTTCYP1A2MAPK1 | |
| SCHEMBL15150 | 0.66 | GAA (0.58) | HSD17B10ALDH1A1HTTCYP1A2MAPK1 | |
| SCHEMBL10942934 | 0.66 | GAA (0.58) | HSD17B10ALDH1A1HTTCYP1A2MAPK1 | |
| SCHEMBL18980526 | 0.65 | HSD17B10 (0.42) | HSD17B10ALDH1A1 | |
| SCHEMBL9374236 | 0.65 | ALDH1A1 (0.48) | HSD17B10ALDH1A1HTTCYP1A2MAPK1 | |
| Acetic Acid SCHEMBL7320116 | 0.65 | HSD17B10 (0.83) | HSD17B10ALDH1A1MAPK1SMN1; SMN2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069325-A1 | Piperidine Derivatives Useful as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069325-A1 | Piperidine Derivatives Useful as Modulators of Chemokine Receptor Activity | CCR3, CCR1, CCR5 | HSD17B10 4007/4885ALDH1A1 606/4885HTT 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.